[Application of peptide bioregulator in complex treatment of elderly cancer patients].
Ias'kevich. L S LS; Krutilina. N I NI; Kostetskaia. T V TV; Ryzhak. G A GA; Khavinson. V Kh VKh
Key Findings
- Adding Vilon to standard cancer treatment was associated with higher 2‑year survival in elderly patients.
- Patients receiving Vilon experienced fewer post‑operative complications and recurrences.
- Quality of life after aggressive treatment appeared improved with Vilon.
Practical Outcomes
- The findings are interesting but not ready for self‑experimentation. No dosage, safety, or larger‑scale data are provided, so biohackers should wait for more robust clinical evidence before considering Vilon as a supplement to cancer therapy.
Summary
A small study looked at adding the peptide Vilon to the usual chemo‑radiation treatment for older people with colon or rectal cancer. The researchers say patients who got Vilon lived longer (about two years), had fewer post‑surgery problems, and felt better overall, but the report is very preliminary and lacks details on dose or safety.
Abstract
Improvement of elderly cancer patients' treatment is an acute issue in oncology. The results of stage III rectal and colon cancer complex treatment are far from being satisfactory in this category of patients. In this connection the search for new adjuvant drugs supplementing radio and chemotherapy is urgent. The article describes pioneer experience in complex radical treatment of elderly cancer patients with immunomodulator Vilon included into the scheme of treatment. The obtained preliminary results of investigation suggest recommendation of Vilon application to increase 2-year survival of patients, prevention of post-operative complications, remote complications, recurrences and tumor dissemination, as well as the improvement of the quality of life after employment of aggressive methods of treatment.
Study Information
pubmed
2005